{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:19:25Z","timestamp":1791235165506,"version":"4.1.0"},"reference-count":62,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Rituximab, a monoclonal antibody targeting CD20, has revolutionized the management of B-cell lymphoproliferative disorders and some immune conditions, significantly improving disease control and patient survival. Beyond its indisputable therapeutic benefits, rituximab can cause serious pulmonary adverse events, particularly interstitial lung disease (R-ILD). Diagnosing R-ILD is challenging due to nonspecific clinical and imagistic features, and its true incidence is possibly underestimated. Methods: We conducted a systematic review to synthesize current evidence on R-ILD, focusing on its incidence, diagnostic approaches, management strategies and clinical outcomes. A comprehensive search of PubMed\/MEDLINE was performed using the term \u201crituximab induced interstitial lung disease\u201d through August 2025. Relevant abstracts were screened, and full-text articles meeting the inclusion criteria were analyzed. Results: A total of 40 studies were retained after the search and screening, including case reports, case series and cohort studies of R-ILD. This condition was identified in both malignant and autoimmune disorders receiving rituximab, more frequently for combination regimens. Radiological manifestations were heterogeneous, and ground-glass opacities were the dominant pattern. Most R-ILD cases were reversible, but progression to chronic interstitial disease and fatal outcomes are possible. Cohort studies demonstrated variability in incidence, reported instances of successful rituximab reintroduction and suggested a protective effect of prophylactic trimethoprim-sulfamethoxazole against opportunistic pneumonitis. Conclusions: Although rare, R-ILD is a clinically significant complication of rituximab therapy. Early recognition and multidisciplinary management are essential, as most patients respond to corticosteroids, while severe cases may progress to respiratory failure or fatal outcomes.<\/jats:p>","DOI":"10.3390\/cancers17233786","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:39:43Z","timestamp":1764167983000},"page":"3786","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab-Induced Interstitial Lung Disease: A Possible Underestimated Complication\u2014A Systematic Review"],"prefix":"10.3390","volume":"17","author":[{"given":"Alexandra-Simona","family":"Zamfir","sequence":"first","affiliation":[{"name":"Department of Medical Sciences III, Pulmonology, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-3059","authenticated-orcid":false,"given":"Mihai-Vasile","family":"Marinca","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Department of Medical Oncology, Regional Institute of Oncology, 700483 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8431-6904","authenticated-orcid":false,"given":"Carmen L\u0103cr\u0103mioara","family":"Zamfir","sequence":"additional","affiliation":[{"name":"Department of Morpho-Functional Sciences I, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-2514","authenticated-orcid":false,"given":"Gabriela","family":"Bordeianu","sequence":"additional","affiliation":[{"name":"Department of Morpho-Functional Sciences II, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5329-7635","authenticated-orcid":false,"given":"Andrada-Larisa","family":"Deac","sequence":"additional","affiliation":[{"name":"Department of Oncology, Emergency County Hospital, 400006 Cluj-Napoca, Romania"},{"name":"Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7911-0699","authenticated-orcid":false,"given":"Bogdan-Mihnea","family":"Ciuntu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Department of General Surgery, County Clinical Emergency Hospital St. Spiridon, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103t\u0103lina Teodora","family":"Pintilie","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doina","family":"Ojog","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Br\u00eenz\u0103","sequence":"additional","affiliation":[{"name":"Clinical Hospital of Pulmonary Diseases Ia\u0219i, 700116 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5690-8638","authenticated-orcid":false,"given":"Tudor Andrei","family":"Cernomaz","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences III, Pulmonology, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Regional Institute of Oncology, 700483 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pierpont, T.M., Limper, C.B., and Richards, K.L. (2018). Past, Present, and Future of Rituximab\u2014The World\u2019s First Oncology Monoclonal Antibody Therapy. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00163"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Carbone, R.G., Puppo, F., Mattar, E., Roden, A.C., and Hirani, N. (2024). Acute and chronic eosinophilic pneumonia: An overview. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1355247"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: An \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2021342118","DOI":"10.1073\/pnas.2021342118","article-title":"CD20 as a gatekeeper of the resting state of human B cells","volume":"118","author":"Jellusova","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.humimm.2019.01.001","article-title":"CD3+CD20+ T cells and their roles in human diseases","volume":"80","author":"Chen","year":"2019","journal-title":"Hum. Immunol."},{"key":"ref_6","first-page":"339","article-title":"Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells","volume":"17","author":"Li","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: Serious adverse events associated with the use of rituximab\u2014A critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit. Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: Implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"160421","DOI":"10.1155\/2014\/160421","article-title":"Rituximab Induced Interstitial Lung Disease in Patients with Non-Hodgkin\u2019s Lymphoma: A Clinical Study of Six Cases and Review of the Literature","volume":"2014","author":"Krishnaswamy","year":"2014","journal-title":"Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ajh.20910","article-title":"Rituximab-induced interstitial lung disease","volume":"82","author":"Wagner","year":"2007","journal-title":"Am. J. Hematol."},{"key":"ref_11","first-page":"284","article-title":"Rituximab Induced Interstitial Lung Disease Diagnosis, Treatment Outcome, and Risk\u2019s Factor, a Place for Transbronchial Pulmonary Cryobiopsy","volume":"10","author":"Douze","year":"2021","journal-title":"Case Rep. Clin. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chari, R., Abdelghany, Y., Purcell, M., and Kenaa, B. (2025). Rituximab induced lung injury. BMC Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03802-x"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00277-023-05303-5","article-title":"Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: A propensity score matching analysis","volume":"102","author":"Liu","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_14","first-page":"527","article-title":"Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies","volume":"104","author":"Zou","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_15","first-page":"349","article-title":"Pneumocystis pneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy","volume":"55","author":"Park","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4103\/0970-2113.168135","article-title":"Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report","volume":"32","author":"Aagre","year":"2015","journal-title":"Lung India"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27178","DOI":"10.3402\/ecrj.v2.27178","article-title":"Rituximab-induced interstitial lung disease: Five case reports","volume":"2","author":"Naqibullah","year":"2015","journal-title":"Eur. Clin. Respir. J."},{"key":"ref_18","first-page":"e28179","article-title":"Myocardial Infarction As the Initial Presentation of Rituximab-Induced Interstitial Lung Disease: A Case Report","volume":"14","author":"Mahmoud","year":"2022","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/jcpt.12198","article-title":"Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: A case report","volume":"39","author":"Kong","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.msard.2018.01.006","article-title":"Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder","volume":"20","author":"Ahn","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/j.1445-5994.2011.02701.x","article-title":"Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura","volume":"42","author":"Child","year":"2012","journal-title":"Intern. Med. J."},{"key":"ref_22","first-page":"e55","article-title":"Rare Presentation of Rituximab-induced Interstitial Lung Disease in a Patient with Pemphigus Vulgaris","volume":"73","author":"Kalyankar","year":"2025","journal-title":"J. Assoc. Physicians India"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ckj\/sft081","article-title":"Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis","volume":"6","author":"Egido","year":"2013","journal-title":"Clin. Kidney J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000327681","article-title":"Rituximab-induced interstitial lung disease: Case report and literature review","volume":"87","author":"Zayen","year":"2011","journal-title":"Pharmacology"},{"key":"ref_25","first-page":"e38910","article-title":"A Rare Presentation of Concomitant Lung Disease and Hepatitis After Rituximab Treatment: A Case Report","volume":"15","author":"Albusoul","year":"2023","journal-title":"Cureus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/jcpt.12052","article-title":"Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-\u03b1 antagonist and cytokine profiling: A case-report and review of the literature","volume":"38","author":"Wu","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000163069","article-title":"Rituximab-induced hypersensitivity pneumonitis","volume":"78","author":"Tonelli","year":"2009","journal-title":"Respiration"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"680431","DOI":"10.1155\/2012\/680431","article-title":"Rituximab-induced bronchiolitis obliterans organizing pneumonia","volume":"2012","author":"Ergin","year":"2012","journal-title":"Case Rep. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4103\/0973-1482.73356","article-title":"Rituximab-induced subacute interstitial pneumonitis: A case report and review of literature","volume":"6","author":"Subramanian","year":"2010","journal-title":"J. Cancer Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2340\/00015555-0817","article-title":"Primary cutaneous intravascular large B-cell lymphoma treated with combination chemotherapy and complicated by rituximab-induced interstitial lung disease","volume":"90","author":"Park","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4065\/79.7.949","article-title":"Rituximab-induced acute pulmonary fibrosis","volume":"79","author":"Leon","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106688","DOI":"10.1016\/j.leukres.2021.106688","article-title":"Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival","volume":"111","author":"Wei","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3349\/ymj.2008.49.1.155","article-title":"Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma","volume":"49","author":"Kim","year":"2008","journal-title":"Yonsei Med. J."},{"key":"ref_34","first-page":"005070","article-title":"From Fibrosis to Granuloma: Drug Induced Systemic Sarcoidosis-Like Reaction After Rituximab in a Patient with Primary Sj\u00f6gren\u2019s Syndrome","volume":"11","author":"Coelho","year":"2024","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1080\/10428190802270886","article-title":"Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma","volume":"49","author":"Liu","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41016-017-0106-3","article-title":"Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: A case report and review of literature","volume":"4","author":"Wu","year":"2018","journal-title":"Chin. Neurosurg. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1177\/0961203312444892","article-title":"Rituximab induced pulmonary fibrosis in a patient with lupus nephritis","volume":"21","author":"Rathi","year":"2012","journal-title":"Lupus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e245837","DOI":"10.1136\/bcr-2021-245837","article-title":"Single dose of rituximab causing organising pneumonia in a patient with B-cell lymphoproliferative disorder","volume":"14","author":"Ban","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3816\/CLM.2006.n.019","article-title":"Fatal interstitial pneumonitis related to rituximab-containing regimen","volume":"6","author":"Herishanu","year":"2006","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1111\/1759-7714.13473","article-title":"Progressive dyspnea and diffuse ground-glass opacities after treatment for lymphoma with rituximab-containing chemotherapy: A case report","volume":"11","author":"Sun","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"bcr2013009105","DOI":"10.1136\/bcr-2013-009105","article-title":"A case series of patients on chemotherapy with dyspnoea and pulmonary infiltrates","volume":"2013","author":"Ullah","year":"2013","journal-title":"BMJ Case Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/RHU.0b013e31823ee5bf","article-title":"Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"18","author":"Arulkumaran","year":"2012","journal-title":"J. Clin. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000104866","article-title":"Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: Case report and review of the literature","volume":"76","author":"Heresi","year":"2008","journal-title":"Respiration"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/hon.799","article-title":"Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin\u2019s lymphoma","volume":"24","author":"Biehn","year":"2006","journal-title":"Hematol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1080\/10428190410001697359","article-title":"Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma","volume":"45","author":"Alexandrescu","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3904\/kjim.2006.21.3.183","article-title":"Two cases of interstitial pneumonitis caused by rituximab therapy","volume":"21","author":"Lee","year":"2006","journal-title":"Korean J. Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3109\/10428190903258780","article-title":"Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma","volume":"50","author":"Katsuya","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1309\/AJCPAFF3RL0SABEJ","article-title":"Increased levels of tumor necrosis factor-\u03b1 involved in rituximab-related acute pulmonary fibrosis in diffuse large B-cell lymphoma","volume":"143","author":"Zhang","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdi232","article-title":"Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy","volume":"16","author":"Ghesquieres","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/03009742.2015.1102963","article-title":"The first case report of fatal acute pulmonary dysfunction in a systemic sclerosis patient treated with rituximab","volume":"45","author":"Nakamura","year":"2016","journal-title":"Scand. J. Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/10428190500144615","article-title":"Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin\u2019s lymphoma following R-CHOP and pegylated filgrastim","volume":"46","author":"Macartney","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.2217\/fon-2019-0694","article-title":"20 years of rituximab treatment: What have we learnt?","volume":"15","author":"Renner","year":"2019","journal-title":"Future Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.autrev.2017.11.015","article-title":"Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and\/or malignant hematological disorders","volume":"17","author":"Tudesq","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kaegi, C., Wuest, B., Schreiner, J., Steiner, U.C., Vultaggio, A., Matucci, A., Crowley, C., and Boyman, O. (2019). Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01990"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00277-017-3160-1","article-title":"Incidence of interstitial pneumonitis in non-Hodgkin\u2019s lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab","volume":"97","author":"Zhou","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non-infectious pulmonary toxicity of rituximab: A systematic review","volume":"51","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology"},{"key":"ref_57","first-page":"PA3860","article-title":"Clinical and radiological correlation of pulmonary complications in CHOP versus rituximab-CHOP regimen treated non-Hodgkin\u2019s lymphoma in Thailand","volume":"50","author":"Kawamatawong","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3904\/kjim.2010.25.1.86","article-title":"Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab","volume":"25","author":"Lim","year":"2010","journal-title":"Korean J. Intern. Med."},{"key":"ref_59","first-page":"86","article-title":"Association of rituximab use with adverse events in adults with lymphoma or autoimmune disease: A single center experience","volume":"12","author":"Hu","year":"2025","journal-title":"Front. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sambataro, D., Sambataro, G., Pignataro, F., Zanframundo, G., Codullo, V., Fagone, E., Martorana, E., Ferro, F., Orlandi, M., and Del Papa, N. (2020). Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?. Diagnostics, 10.","DOI":"10.3390\/diagnostics10040208"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s00277-022-04913-9","article-title":"Can we restart the rituximab after remission of rituximab-induced interstitial lung disease in malignant lymphoma?","volume":"101","author":"Zhang","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3786\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T12:02:59Z","timestamp":1764244979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":62,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17233786"],"URL":"https:\/\/doi.org\/10.3390\/cancers17233786","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}